CN108014237A - 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 - Google Patents
一种治疗骨裂或骨折的药物组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN108014237A CN108014237A CN201711332439.4A CN201711332439A CN108014237A CN 108014237 A CN108014237 A CN 108014237A CN 201711332439 A CN201711332439 A CN 201711332439A CN 108014237 A CN108014237 A CN 108014237A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- pharmaceutical composition
- pharmaceutical chemicals
- bulk pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000000126 substance Substances 0.000 claims abstract description 31
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 19
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 19
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 19
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 19
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 19
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 19
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004863 Frankincense Substances 0.000 claims abstract description 19
- 241000212321 Levisticum Species 0.000 claims abstract description 19
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 19
- 239000010949 copper Substances 0.000 claims abstract description 19
- 229910052802 copper Inorganic materials 0.000 claims abstract description 19
- 239000009136 dragon's blood Substances 0.000 claims abstract description 19
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 18
- 241001148782 Davallia Species 0.000 claims abstract description 18
- 241001465251 Ephedra sinica Species 0.000 claims abstract description 18
- 230000000295 complement effect Effects 0.000 claims abstract description 7
- 241001043298 Croton draco Species 0.000 claims abstract 5
- 239000000843 powder Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000012467 final product Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 239000006187 pill Substances 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- -1 decoction Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 238000009702 powder compression Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 240000009023 Myrrhis odorata Species 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 208000010392 Bone Fractures Diseases 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 240000004824 Trimezia steyermarkii Species 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- RZYKUPXRYIOEME-UHFFFAOYSA-N CCCCCCCCCCCC[S] Chemical compound CCCCCCCCCCCC[S] RZYKUPXRYIOEME-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种药物组合物,属于中医药领域。该药物组合物是由下述重量配比的原料药制备而成的制剂:乳香2~40份、没药10~45份、血竭8~45份、羌活10~50份、独活5~40份、骨碎补7~40份、红花2~40份、土鳖虫5~40份、麻黄2~30份、自然铜5~25份。本发明还提供了该药物组合物的制备方法和用途。临床试验证明,本发明药物组合物配伍精当,各药味相辅相成,无毒副作用,能有效治疗骨裂或骨折复位后的愈合,具有较强的实际应用价值。
Description
技术领域
本发明属于中医药领域,具体涉及一种治疗骨裂或骨折的药物组合物及其制备方法和用途。
背景技术
骨折系指由于外伤或病理等原因致使骨质部分地或完全地断裂的一种疾病。骨裂在医学上称为裂纹骨折,属骨折类型中的一种。多见于儿童及老年人,中青年也时有发生。病人常为一个部位骨折,少数为多发性骨折。经及时恰当处理,多数病人能恢复原来的功能,少数病人可留有不同程度的后遗症。骨折治疗期间病人一般需卧床2-3个月,给病人的生活带来不便。现有的各种药物或者疗效难如人意,或者有一定的副作用,或者成本较高。
现未见将乳香、没药、血竭、羌活、独活、骨碎补、红花、土鳖虫、麻黄和自然铜配合用于治疗骨裂或骨折复位后的愈合的报道。
发明内容
本发明提供了一种治疗骨裂或骨折的药物组合物及其制备方法和用途。
本发明提供了一种药物组合物,它是由下述重量配比的原料药制备而成的制剂:乳香2~40份、没药10~45份、血竭8~45份、羌活10~50份、独活5~40份、骨碎补7~40份、红花2~40份、土鳖虫5~40份、麻黄2~30份、自然铜5~25份。
优选地,它是由下述重量配比的原料药制备而成的制剂:乳香5~30份、没药10~35份、血竭8~30份、羌活10~38份、独活10~34份、骨碎补7~30份、红花10~35份、土鳖虫15~30份、麻黄2~25份、自然铜5~20份。
更优选地,它是由下述重量配比的原料药制备而成的制剂:乳香20份、没药20份、血竭20份、羌活20份、独活20份、骨碎补20份、红花20份、土鳖虫20份、麻黄10份、自然铜10份。
前述组合物是以乳香、没药、血竭、羌活、独活、骨碎补、红花、土鳖虫、麻黄、自然铜的药粉,或者水或有机溶剂提取物为有效成分,加上药学上可接受的辅料制备成药学上常用的制剂。
本发明所述“药学上可接受的辅料”,是指除活性成分以外包含在剂型中的物质,包括但不仅限于填充剂(稀释剂)、润滑剂(助流剂或抗粘着剂)、分散剂、湿润剂、粘合剂、调节剂、增溶剂、抗氧剂、抑菌剂、乳化剂、崩解剂等。粘合剂包含糖浆、阿拉伯胶、明胶、山梨醇、黄芪胶、纤维素及其衍生物(如微晶纤维素、羧甲基纤维素钠、乙基纤维素或羟丙甲基纤维素等)、明胶浆、糖浆、淀粉浆或聚乙烯吡咯烷酮等;填充剂包含乳糖、糖粉、糊精、淀粉及其衍生物、纤维素及其衍生物、无机钙盐(如硫酸钙、磷酸钙、磷酸氢钙、沉降碳酸钙等)、山梨醇或甘氨酸等;润滑剂包含微粉硅胶、硬脂酸镁、滑石粉、氢氧化铝、硼酸、氢化植物油、聚乙二醇等;崩解剂包含淀粉及其衍生物(如羧甲基淀粉钠、淀粉乙醇酸钠、预胶化淀粉、改良淀粉、羟丙基淀粉、玉米淀粉等)、聚乙烯吡咯烷酮或微晶纤维素等;湿润剂包含十二烷基硫酸钠、水或醇等;抗氧剂包含亚硫酸钠、亚硫酸氢钠、焦亚硫酸钠、二丁基苯酸等;抑菌剂包含0.5%苯酚、0.3%甲酚、0.5%三氯叔丁醇等;调节剂包含盐酸、枸橼酸、氢氧化钾(钠)、枸橼酸钠及缓冲剂(包括磷酸二氢钠和磷酸氢二钠)等;乳化剂包含聚山梨酯-80、脂肪酸山梨坦、普流罗尼克F-68,卵磷酯、豆磷脂等;增溶剂包含吐温-80、胆汁、甘油等。
所述药学上可接受的辅助性成分,它具有一定生理活性,但该成分的加入不会改变上述化合物或衍生物在疾病治疗过程中的主导地位,而仅仅发挥辅助功效,这些辅助功效仅仅是对该成分已知活性的利用,是医药领域惯用的辅助治疗方式。若将上述辅助性成分与本发明化合物配合使用,仍然应属于本发明保护的范围。
其中,所述制剂为口服制剂。
其中,所述制剂为散剂、汤剂、颗粒剂、片剂、胶囊剂、口服液、丸剂。
本发明还提取前述的药物组合物的制备方法,它包含如下步骤:
(1)称取各重量配比的原料药;
(2)原料药直接打粉,或将原料药加水煎煮或有机溶剂提取,提取液浓缩,再加入药学上可接受的辅料或辅助性成分制备成药学上常用的制剂。
水提物或以药粉入药,均是中药传统使用方式,水提后,由于水的溶解范围广,能够将大部分有效成分溶出,使药物更容易被人体吸收,起效更快,例如汤剂等给药形式;以原粉入药,药粉的表面积较大,也有利于药材中有效成分在体内的吸收,但药材未经提取,有效成分仍需在体内溶出再吸收,其起效相对水提物较慢,但也同时削弱了药材中有害成分对人体造成的毒副反应,适合于长期服用,如将原粉制备成丸剂等给药形式。目前在制药过程中,乙醇作为溶剂对药物进行提取,也是最为常见的提取方式之一,乙醇为半极性溶剂,溶解性能界于极性与非极性溶剂之间,可以溶解水溶性的某些成分,也能溶解非极性溶剂溶解的一些成分,通常用乙醇提取代替水煎,从而避免大量无效成分的溶出,提高有效成分的浓度和提取效率,不过乙醇的价格较水贵,在现代制药工业大生产中,为了节省生产成本,通常还是以水煎为主。在本发明已知组合物的水提物具有生理活性的情况下,为了适应各种生产和使用时的需求,可以任选水提、原粉、醇提或它们的组合方法来制备具体的剂型。
其中,具体制备方法如下:
散剂:称取原料药,打粉,过筛,即得;
汤剂:称取原料药,煎煮,过滤,即得;
颗粒剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩、干燥,加入辅料或辅助性成分,混匀,制粒、整粒、干燥,即得;
片剂:称取原料药,打粉,粉末直接压片,即得;
胶囊剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩干燥,加入辅料或辅助性成分,混匀,装胶囊,即得;
水丸:称取原料药,打粉,过筛,加入赋形剂,水泛丸,干燥,即得;
蜜丸:称取原料药,打粉,过筛,加入蜂蜜,制丸,干燥,即得;
滴丸:称取原料药,加水或有机溶剂提取,过滤,滤液中加入基质,混匀加热融化,滴入不相混溶的冷凝液中冷凝,即得。
所述的有机溶剂为不同浓度的乙醇,如25%-95%的乙醇。
本发明最后提供前述的药物组合物在制备治疗骨裂或骨折复位后愈合的药物中的用途。
气血是人体活动的物质基础。《素问调经论》说:“人之所有者,血与气耳”。《难经.二十二难》说:“气主煦之,血主濡之。”气有温煦的用,血有濡养的功能,四肢百骸,五脏六腑,皆赖气血以濡养。骨骼是人体的重要组成部分。当然也离不开气血的充养。《灵枢.经脉篇》说:“上焦出气,以温分肉而养骨节”。《灵枢.本藏篇》又说:“经脉者,所以行气血而荣阴阳,濡筋骨,利关节者也”。说明了气血是充养骨骼的重要物质。经脉畅通,气血调和,骨骼就能得充养而使筋骨劲强。据此可以认为:骨折以后,必须经脉畅通,气血调和才能愈合。倘使气滞血瘀,经脉闭塞,则气血不和,断端得不到滋养,就难以愈合。《圣济总录.伤折门》云:“人之一身,血荣气卫,循环无穷,或筋肉骨节,误致所伤折,则气血淤滞疼痛,所伤不得完,所折不得续”。“脉者血之府,血行脉中,贯于肉理,环周一身,因其肌体外固,经脉内通,乃能流注不失其常。若因伤折,内动经络,血行之道,不得宣通,淤积不散,为肿为痛,治宜除去恶淤,使气血流通,则可复完也。.陈士铎《百病辨证录》说:“血不活者淤不去,淤不去则骨不能接也。”
气血是充养骨骼的重要物质。每当骨折以后,如气血旺盛,就能加快断端连接;反之,如气血不足,骨折就难愈合。
《素问.宣明五气篇》说:“肾主骨”;《阴阳应象大论》说:“肾生骨髓”;《六节藏象论》还说:“肾者,其充在骨”。提示肾脏的精气,能生养骨骼。肾气旺盛则骨骼生长,肾气衰退则骨骼亦随之衰退。
本发明药物组合物强壮了主体骨质,而正是由于此,使得骨折或骨裂得以好转乃至康复。
本发明药物组合物中,乳香、没药为君药,活血定痛,散瘀定痛,消肿生肌;血竭、羌活为臣药,化瘀止血,生肌敛疮,止痛;佐以独活、骨碎补、红花、土鳖虫,通痹止痛,补肾强骨,破瘀血,续筋骨;再以麻黄宣发之力助药力发散,借自然铜接骨之特殊疗效作用于患处。
本发明药物组合物能明显改善骨裂或骨折复位后的状况,使患者愈合,无毒副作用,具有较强的实际应用价值。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
实施例1本发明药物片剂的制备
取乳香20g、没药20g、血竭20g、羌活20g、独活20g、骨碎补20g、红花20g、土鳖虫20g、麻黄10g、自然铜10g,打粉,粉末直接压片,即得片剂。
实施例2本发明药物汤剂的制备
取乳香2g、没药35g、血竭8g、羌活38g、独活5g、骨碎补7g、红花2g、土鳖虫30g、麻黄2g、自然铜5g,加水浸泡煎煮,合并滤液,过滤,即得汤剂。
实施例3本发明药物胶囊剂的制备
乳香30g、没药10g、血竭30g、羌活50g、独活34g、骨碎补30g、红花35g、土鳖虫5g、麻黄25g、自然铜20g,加水煎煮提取、浓缩成浸膏,加入辅料,混匀,分装,即得胶囊剂。
实施例4本发明药物水丸的制备
乳香40g、没药10g、血竭45g、羌活10g、独活10g、骨碎补40g、红花40g、土鳖虫15g、麻黄30g、自然铜5g,打粉,过筛,加入赋形剂,水泛丸,干燥,即得水丸。
实施例5本发明药物蜜丸的制备
乳香5g、没药45g、血竭8g、羌活10g、独活40g、骨碎补7g、红花10g、土鳖虫40g、麻黄2g、自然铜25g,打粉,过筛,加入蜂蜜,制丸,干燥,即得蜜丸。
实施例6本发明药物片剂的制备
取乳香25g、没药10g、血竭15g、羌活20g、独活24g、骨碎补18g、红花25g、土鳖虫30g、麻黄12g、自然铜15g,打粉,粉末直接压片,即得片剂。
实施例7本发明药物片剂的制备
取乳香10g、没药25g、血竭20g、羌活15g、独活25g、骨碎补20g、红花20g、土鳖虫20g、麻黄16g、自然铜10g,用乙醇提取,得到乙醇提取液,浓缩成浸膏,加入淀粉制粒、整粒、压片,即得片剂。
实施例8本发明药物口服液的制备
取乳香25g、没药20g、血竭20g、羌活15g、独活20g、骨碎补20g、红花23g、土鳖虫20g、麻黄15g、自然铜10g,加水浸泡煎煮,合并滤液,浓缩,灌封,灭菌,即得口服液。
以下通过具体临床试验证明本发明的有益效果:
试验例1本发明药物组合物治疗骨裂或骨折复位后的临床疗效
1实验材料
1.1实验药物
本发明药物组合物,由实施例1制备而成。
1.2患者资料
观察病例共55例,年龄平均43岁。
2实验方法
2.1纳入病例标准
经《西医病症诊断疗效标准》,①确诊为骨折的患者。②确诊为骨裂的患者。
2.2排除病例标准
①孕妇、对本药过敏者。
②合并有心血管、肝、肾和造血系统等严重原发性疾病,精神病患者。
③凡不符合纳入标准,未按规定用药,无法判断疗效或资料不全等影响疗效或安全性判断者。
2.3疗效判断
治愈:关节结构正常,症状消失,功能完全或基本恢复。
好转:关节结构正常,症状改善,功能部分受限。
未愈:脱位未复位,症状无改善,功能障碍。
2.4给药方法
本药每日服用3次,早、中、晚各服用一次,需以黄酒或红酒送服,以助药力,每次服用的药物的重量相当于3克生药。
3实验结果
| 组别 | 治愈(例) | 好转(例) | 未愈(例) | 总有效率 |
| 治疗组 | 55 | 0 | 0 | 100% |
实验结果说明,服用1个月可见明显效果,本发明药物组合物,总有效率100%,本发明药物组合物能有效改善骨裂或骨折复位后的状况。
试验例2本发明药物组合物治疗骨裂或骨折复位后的典型病例
胡XX,男35岁,骑电动车与自行车相撞摔伤,导致挠骨骨折,疼痛难忍,服用本药当天即止痛,后20余天痊愈。
综上,本发明药物组合物强壮了主体骨质,能明显改善骨裂或骨折复位后的状况,使患者愈合,减轻患者痛苦,无毒副作用,具有较强的实际应用价值。
Claims (9)
1.一种药物组合物,其特征在于:它是由下述重量配比的原料药制备而成的制剂:乳香2~40份、没药10~45份、血竭8~45份、羌活10~50份、独活5~40份、骨碎补7~40份、红花2~40份、土鳖虫5~40份、麻黄2~30份、自然铜5~25份。
2.根据权利要求1所述的药物组合物,其特征在于:它是由下述重量配比的原料药制备而成的制剂:乳香5~30份、没药10~35份、血竭8~30份、羌活10~38份、独活10~34份、骨碎补7~30份、红花10~35份、土鳖虫15~30份、麻黄2~25份、自然铜5~20份。
3.根据权利要求2所述的药物组合物,其特征在于:它是由下述重量配比的原料药制备而成的制剂:乳香20份、没药20份、血竭20份、羌活20份、独活20份、骨碎补20份、红花20份、土鳖虫20份、麻黄10份、自然铜10份。
4.根据权利要求1-3任意一项所述的药物组合物,其特征在于:所述组合物是以乳香、没药、血竭、羌活、独活、骨碎补、红花、土鳖虫、麻黄、自然铜的药粉,或者水或有机溶剂提取物为有效成分,加上药学上可接受的辅料制备成药学上常用的制剂。
5.根据权利要求4所述的药物组合物,其特征在于:所述制剂为口服制剂。
6.根据权利要求5所述的药物组合物,其特征在于:所述制剂为散剂、汤剂、颗粒剂、片剂、胶囊剂、口服液或丸剂。
7.权利要求1-6任意一项所述的药物组合物的制备方法,其特征在于:它包含如下步骤:
(1)称取各重量配比的原料药;
(2)原料药直接打粉,或将原料药加水煎煮或有机溶剂提取,提取液浓缩,再加入药学上可接受的辅料或辅助性成分制备成药学上常用的制剂。
8.根据权利要求7所述的制备方法,其特征在于:具体制备方法如下:
散剂:称取原料药,打粉,过筛,即得;
汤剂:称取原料药,煎煮,过滤,即得;
颗粒剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩、干燥,加入辅料或辅助性成分,混匀,制粒、整粒、干燥,即得;
片剂:称取原料药,打粉,粉末直接压片,即得;
胶囊剂:称取原料药,加水或有机溶剂提取,过滤,滤液浓缩干燥,加入辅料或辅助性成分,混匀,装胶囊,即得;
水丸:称取原料药,打粉,过筛,加入赋形剂,水泛丸,干燥,即得;
蜜丸:称取原料药,打粉,过筛,加入蜂蜜,制丸,干燥,即得;
滴丸:称取原料药,加水或有机溶剂提取,过滤,滤液中加入基质,混匀加热融化,滴入不相混溶的冷凝液中冷凝,即得。
9.权利要求1-6任意一项所述的药物组合物在制备治疗骨裂或骨折药物中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711332439.4A CN108014237A (zh) | 2017-12-13 | 2017-12-13 | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711332439.4A CN108014237A (zh) | 2017-12-13 | 2017-12-13 | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108014237A true CN108014237A (zh) | 2018-05-11 |
Family
ID=62073510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711332439.4A Pending CN108014237A (zh) | 2017-12-13 | 2017-12-13 | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108014237A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310022A (zh) * | 2018-05-14 | 2018-07-24 | 王金华 | 一种药物组合物在治疗骨病中使用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1138482A (zh) * | 1996-03-25 | 1996-12-25 | 刘建明 | 一种治疗骨折的药物及长骨贴 |
-
2017
- 2017-12-13 CN CN201711332439.4A patent/CN108014237A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1138482A (zh) * | 1996-03-25 | 1996-12-25 | 刘建明 | 一种治疗骨折的药物及长骨贴 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310022A (zh) * | 2018-05-14 | 2018-07-24 | 王金华 | 一种药物组合物在治疗骨病中使用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105106440B (zh) | 一种治疗腰麻后头痛头晕的中药组合物 | |
| CN108014237A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
| CN103071076B (zh) | 一种足浴护理促进剖宫产术后恢复的中药组合物及应用 | |
| CN108014236A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
| CN108159236A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
| CN101632783B (zh) | 一种中药组合物在制备治疗肺原性心脏病药物中的应用 | |
| CN108126077A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
| CN108042678A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
| CN107998252A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
| CN107913374A (zh) | 一种治疗结石的药物组合物及其制备方法 | |
| CN108014238A (zh) | 一种治疗骨折、骨裂的药物组合物及其制备方法 | |
| US20200113958A1 (en) | Compositions and Methods For Balancing Body Acidity and Relieving Body Over Acidity Symptoms and Strengthening the Immune Response | |
| CN108186854A (zh) | 一种治疗骨折、骨裂的药物组合物及其制备方法 | |
| CN115554345B (zh) | 一种治疗痛风及高尿酸血症的中药复方制剂及其制法 | |
| CN107929354A (zh) | 一种治疗结石的药物组合物及其制备方法和用途 | |
| CN102018787B (zh) | 一种用于降血压的胶囊及制作工艺 | |
| CN108126076A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
| CN107998253A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
| CN108042679A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
| CN108014235A (zh) | 一种治疗骨折或骨裂的药物组合物及其制备方法和用途 | |
| CN1973871B (zh) | 一种治疗咽喉炎的药物组合物及其制备方法 | |
| CN105687499A (zh) | 一种含有倍他洛尔的治疗高血压的药物组合物及其制备方法 | |
| CN100496547C (zh) | 一种治疗感冒的中药制剂 | |
| CN105535658A (zh) | 一种治疗口腔溃疡的中药组合物及其制备方法 | |
| CN104225014B (zh) | 一种治疗糖尿病的藏药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180511 |
|
| WD01 | Invention patent application deemed withdrawn after publication |